Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Posi ...Middle East

Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a 50.7% Objective Response Rate (ORR), 23.0-month Median Duration of Response (DOR), and Median Overall Survival (OS) of 18.4 months Safety findings consistent with prior studies with no reports of cytokine release...

Hence then, the article about updated results of phase 3 allele study presented at 66th american society of hematology annual meeting confirm efficacy safety and durability of novel allogeneic cell therapy tabelecleucel in relapsed or refractory epstein barr virus posi was published today ( Saturday 07/12/2024 - 08:36 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Posi )

Also on site :

• Physicists just witnessed pinpricks of darkness moving faster than the speed of light ‪—‬ without breaking the laws of relativity
• China has so far weathered the historic oil crisis. But as Xi prepares to meet Trump, costs are starting to grow
• 1967 Classic Rock Anthem Ranked Among the ‘Greatest Songs of All Time’—‘One of the Most Beautiful Songs Ever Written’